2 documents found, page 1 of 1
Idiopathic Pulmonary Fibrosis in the Era of Antifibrotic Therapy: Searching for...
Robalo-Cordeiro, C; Campos, P; Carvalho, L; Borba, A; Clemente, S; Freitas, S; Furtado, S; Jesus, JM; Leal, C; Marques, A; Melo, N; Souto-Moura, CIdiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that up to now has been associated with a poor prognosis. However, the results of the INPULSIS and ASCEND trials and the approval of nintedanib and pirfenidone have marked the beginning of a new era for IPF patients. Questions remain, however. Should these drugs be used earlier? What effect will they have on more severe disease? Will th...
Idiopathic pulmonary fibrosis--clinical presentation, outcome and baseline prog...
Soares Pires, F; Caetano Mota, P; Melo, N; Costa, D; Jesus, JM; Cunha, RIntroduction: Idiopathic Pulmonary Fibrosis (IPF) is the most common disease in the subgroup of idiopathic interstitial pneumonias. It is inevitably associated to a bad prognosis, although assuming a highly variable clinical course. Methods: Patients with IPF, observed at Interstitial Lung Diseases outpatient clinic of Centro Hospitalar de São João – Porto, Portugal, were identified and clinical, functional, ra...